Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

If Fibrosis/Cirrhosis regression as proven by biopsy is significantly more than placebo, the implications will be huge, as the POLT SRV HCV patients population is relatively small, but we know that Emricasan is effective regardless of etiology (NASH;HCV; HBV, alcohol, etc ) . So it would open up a potential market of 50M Liver Cirrhosis patients, plus the liver fibrotic stages, plus potential caspase inhibitors applications to other organs fibrosis.
So I do not have an exact short term target price, I only know that 2/3 of global deaths are due to some kind of organs fibrosis, and that there is currently no cure/treatment.
If caspase inhibitors safely reverse cirrhosis/fibrosis not only in Liver but also in other organs then CNAT will be trading in the (tens of) thousands $$ within a few years.